Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
How It Works 
News - Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI Summary - About
Alaunos Therapeutics Inc(TCRT)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Stock price based on last close Advisory Performance History (Simulated)
Upturn Advisory & Investor View for TCRT
10/29/2026: TCRT (1-star) is currently NOT-A-BUY. Pass it for now.
Alaunos Therapeutics is a restructured, pre-revenue biotechnology company now focused on developing treatments for pulmonary arterial hypertension and related conditions. Following a transformative 2026 reverse merger with Velaris Therapeutics, the company has secured a significant cash runway that supports operations through 2029. Its primary opportunity lies in its pipeline of ActRII-Fc ligand traps, with proof-of-concept data expected in 2028. However, the company faces substantial risks, including early-stage scientific uncertainty, intense competition from major pharmaceutical players, and high shareholder dilution. It is best suited for speculative investors interested in clinical catalysts, though it requires close monitoring of clinical progress and listing compliance status.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Mixed fit | The company offers high growth potential through clinical breakthroughs, but is tempered by extreme early-stage risk. |
| Momentum investor | Strong fit while signal remains positive | Recent event-driven catalysts and restructuring have created high, albeit volatile, momentum for the stock. |
| Value investor | Weak fit | The company is a pre-revenue, speculative entity without stable cash flows to support traditional valuation metrics. |
| Dividend investor | Weak fit | There is no dividend policy and capital is entirely directed toward high-burn R&D activities. |
| Low-risk investor | Weak fit | Extreme volatility, binary clinical risks, and dilution concerns make this unsuitable for low-risk portfolios. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | High | Speculative biotech nature leads to frequent, extreme percentage swings based on news flow. |
| Valuation risk | High | Heavy dilution and pre-revenue status make intrinsic valuation difficult and highly dependent on future data. |
| Competition risk (Cardiopulmonary) | High | The company faces entrenched incumbents with vastly superior resources in the pulmonary market. |
| Business quality | Medium | Transition to a new, better-funded pipeline improves quality, but the preclinical portfolio remains unproven. |
| Dividend income | Low / none | Capital is preserved for R&D; zero expectation for income. |
| Execution risk | High | Management must successfully navigate a long clinical roadmap with no margin for error. |
Price Behavior
Steep Decline
The stock price has dropped sharply with strong downward pressure.
Extreme Price Shocks
The stock has experienced exceptionally large and disruptive price movements during the period.
Analysis of Past Performance
Type Stock | Historic Profit -60.99% | Avg. Invested days 16 | Today’s Advisory PASS |
Upturn Advisory Rating  | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/29/2026 |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals
Financial Health Rating
Growth Momentum Score
Ownership
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue)
Economic Dimensions
Quantitative Style Profile
Style Classification
Quality Focused
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 7.33M USD | Price to earnings Ratio - | 1Y Target Price 1.75 |
Price to earnings Ratio - | 1Y Target Price 1.75 | ||
Volume (30-day avg) 15.5M shares | Beta -0.87 | 52 Weeks Range 0.72 - 4.50 | Updated Date 10/29/2026 |
52 Weeks Range 0.72 - 4.50 | Updated Date 10/29/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.76 |
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Cardiopulmonary R&D | Clinical and preclinical development of ActRII-Fc ligand traps for PAH. | The company is currently spending cash to develop drugs and does not yet generate sales. |
Valuation
Trailing PE - | Forward PE 18.48 | Enterprise Value 5.29M | Price to Sales(TTM) 2442.88 |
Enterprise Value 5.29M | Price to Sales(TTM) 2442.88 | ||
Enterprise Value to Revenue 1694.66 | Enterprise Value to EBITDA -3.55 | Shares Outstanding 3.44M | Shares Floating 1.20M |
Shares Outstanding 3.44M | Shares Floating 1.20M | ||
Percent Insiders 12.41 | Percent Institutions 23.25 |
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.